- Knowledge center
Fusion transcripts are hallmarks and common drivers in cancer, making them ideal targets for diagnostic and therapeutic purposes. At Biogazelle RNA sequencing technology is used to study transcriptome wide fusion genes in RNA, whereas digital PCR is used for detection of known fusion genes in DNA or RNA.
Take your clinical study to the next level with fusion gene biomarkers:
screen unbiased for expressed fusion genes or detect known fusion genes
in your clinical samples.
Paired-end RNA sequencing offers a great opportunity to detect somatic fusion transcripts in cancer samples. Biogazelle has developed an RNA sequencing based workflow, applicable on clinically relevant sample types (including FFPE tissue and plasma samples), for the unbiased detection of fusion genes.
Biogazelle offers targeted detection and quantification of specific fusion genes using digital PCR. This method is compatible with a wide range of samples, including FFPE tissue and plasma samples. Patient specific fusion genes can for instance be monitored in plasma during treatment. While off-the-shelf assays are available for some common fusion genes (EML4-ALK, RET, ROS1), Biogazelle offers custom design and validation for specific fusion genes of interest.